NO931372D0 - Behandling av autoimmunsykdommer ved oral administrering av autoantigener - Google Patents

Behandling av autoimmunsykdommer ved oral administrering av autoantigener

Info

Publication number
NO931372D0
NO931372D0 NO931372A NO931372A NO931372D0 NO 931372 D0 NO931372 D0 NO 931372D0 NO 931372 A NO931372 A NO 931372A NO 931372 A NO931372 A NO 931372A NO 931372 D0 NO931372 D0 NO 931372D0
Authority
NO
Norway
Prior art keywords
auto
oral administration
treatment
immune diseases
antigens
Prior art date
Application number
NO931372A
Other languages
English (en)
Other versions
NO314878B1 (no
NO931372L (no
Inventor
Howard L Weiner
David A Hafler
Original Assignee
Brigham & Womens Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Brigham & Womens Hospital filed Critical Brigham & Womens Hospital
Publication of NO931372D0 publication Critical patent/NO931372D0/no
Publication of NO931372L publication Critical patent/NO931372L/no
Publication of NO314878B1 publication Critical patent/NO314878B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/35—Allergens
    • A61K39/36—Allergens from pollen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Rheumatology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
NO19931372A 1990-10-15 1993-04-14 Fremgangsmåte for fremstilling av et farmasöytisk preparat for behandling av reumatoid artritt og multippel sklerose NO314878B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US59693690A 1990-10-15 1990-10-15
PCT/US1991/007542 WO1992006708A1 (en) 1990-10-15 1991-10-15 Treatment of autoimmune diseases by oral administration of autoantigens

Publications (3)

Publication Number Publication Date
NO931372D0 true NO931372D0 (no) 1993-04-14
NO931372L NO931372L (no) 1993-05-18
NO314878B1 NO314878B1 (no) 2003-06-10

Family

ID=24389347

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19931372A NO314878B1 (no) 1990-10-15 1993-04-14 Fremgangsmåte for fremstilling av et farmasöytisk preparat for behandling av reumatoid artritt og multippel sklerose

Country Status (13)

Country Link
US (1) US6019971A (no)
EP (1) EP0553291B1 (no)
JP (1) JP2635444B2 (no)
KR (1) KR0140841B1 (no)
AT (1) ATE319474T1 (no)
AU (2) AU9023791A (no)
CA (1) CA2092905C (no)
DE (1) DE69133516T2 (no)
ES (1) ES2258261T3 (no)
HU (1) HUT69942A (no)
IL (1) IL99754A (no)
NO (1) NO314878B1 (no)
WO (1) WO1992006708A1 (no)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5869054A (en) * 1987-06-24 1999-02-09 Autoimmune Inc. Treatment of multiple sclerosis by oral administration of autoantigens
US5843445A (en) * 1987-06-24 1998-12-01 Autoimmune, Inc. Method of treating rheumatoid arthritis with type II collagen
US5849298A (en) * 1987-06-24 1998-12-15 Autoimmune Inc. Treatment of multiple sclerosis by oral administration of bovine myelin
US6645504B1 (en) 1987-06-24 2003-11-11 Autoimmune Inc. Bystander suppression of type I diabetes by oral administration of glucagon
JP2635444B2 (ja) * 1990-10-15 1997-07-30 オートイミューン インク 自己抗体の経口投与による自己免疫性疾患の治療
US6613332B1 (en) 1991-06-21 2003-09-02 The University Of Cincinnati Oral administration of therapeutic proteins
EP0590060B1 (en) * 1991-06-21 1997-09-17 University Of Cincinnati Orally administrable therapeutic proteins and method of making
DE4125400C2 (de) * 1991-07-31 2000-08-17 Edwin Klaus Verwendung von unlöslichem Kollagen zur Behandlung von degenerativen, nicht entzündlichen Gelenkprozessen
KR950700082A (ko) * 1992-02-28 1995-01-16 로버트 씨. 비숍 바이스탠더(bystander)에 의한 자가면역질환을 처치하는 방법
EP0662838A4 (en) * 1992-09-25 1996-07-24 Autoimmune Inc PROCESS FOR THE TREATMENT OF RHUMATOID POLYARTHRITIS WITH TYPE II COLLAGEN.
SG52402A1 (en) * 1992-12-22 1998-09-28 Univ Cincinnati Oral administration of immunologically active biomolecules and other therapeutic proteins
EP0609471B1 (de) * 1993-02-02 2000-01-05 Edwin Dr. Klaus Verwendung von Kollagen zur Behandlung von krankhaften Gelenkprozessen
CA2164326A1 (en) * 1993-06-02 1994-12-08 Wayne Robert Thomas Cryptic peptides for use in inducing immunologic tolerance
GB9319429D0 (en) 1993-09-21 1993-11-03 London Health Ass Methods and products for controlling immune responses in mammals
US6379670B1 (en) 1994-11-18 2002-04-30 Neurocrine Biosciences, Inc. Methods for treatment of multiple sclerosis using peptide analogs of human myelin basic protein
US6251396B1 (en) 1994-11-18 2001-06-26 Neurocrine Biosciences, Inc. Methods for treatment of multiple sclerosis using peptide analogs of human myelin basic protein
US5856446A (en) * 1995-07-07 1999-01-05 Autoimmune Inc. Method of treating rheumatoid arthritis with low dose type II collagen
ATE423568T1 (de) * 1996-01-05 2009-03-15 Autoimmune Inc Methode zur herstellung von type-ii kollagen
WO1997046253A2 (en) * 1996-06-03 1997-12-11 Powderject Vaccines, Inc. Immunotherapy for autoimmune disease
AU3825497A (en) * 1996-08-15 1998-03-06 Agrivax Incorporated Delivery of tolerogenic antigens via edible plants or plant-derived products
US6787523B1 (en) 1997-12-02 2004-09-07 Neuralab Limited Prevention and treatment of amyloidogenic disease
US6923964B1 (en) 1997-12-02 2005-08-02 Neuralab Limited Active immunization of AScr for prion disorders
US6710226B1 (en) 1997-12-02 2004-03-23 Neuralab Limited Transgenic mouse assay to determine the effect of Aβ antibodies and Aβ Fragments on alzheimer's disease characteristics
US6750324B1 (en) 1997-12-02 2004-06-15 Neuralab Limited Humanized and chimeric N-terminal amyloid beta-antibodies
US6913745B1 (en) 1997-12-02 2005-07-05 Neuralab Limited Passive immunization of Alzheimer's disease
US20080050367A1 (en) 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
US7790856B2 (en) 1998-04-07 2010-09-07 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
US6905686B1 (en) 1997-12-02 2005-06-14 Neuralab Limited Active immunization for treatment of alzheimer's disease
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US7691829B2 (en) * 1998-03-24 2010-04-06 Petito George D Composition and method for healing tissues
US20050208114A1 (en) * 1998-03-24 2005-09-22 Petito George D Composition and method for healing tissues
US20030147882A1 (en) 1998-05-21 2003-08-07 Alan Solomon Methods for amyloid removal using anti-amyloid antibodies
US6787637B1 (en) 1999-05-28 2004-09-07 Neuralab Limited N-Terminal amyloid-β antibodies
UA81216C2 (en) 1999-06-01 2007-12-25 Prevention and treatment of amyloid disease
EP1286664B1 (en) * 2000-05-12 2007-07-25 Oregon Health and Science University Combination of low dose estrogen and immunotherapeutic agent for treating immune diseases
US7462486B2 (en) * 2000-05-12 2008-12-09 Oregon Health & Science University Methods of selecting T cell receptor V peptides for therapeutic use
PT1286686E (pt) 2000-05-24 2007-11-07 Us Health E-selectiva para o tratamento ou prevenção do acidente vascular cerebral
US7700751B2 (en) 2000-12-06 2010-04-20 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize β-amyloid peptide
MY139983A (en) 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
PE20050627A1 (es) 2003-05-30 2005-08-10 Wyeth Corp Anticuerpos humanizados que reconocen el peptido beta amiloideo
US8053197B2 (en) * 2004-07-30 2011-11-08 Oregon Health & Science University Methods for detecting and treating autoimmune disorders
WO2006066089A1 (en) 2004-12-15 2006-06-22 Neuralab Limited Humanized amyloid beta antibodies for use in improving cognition
WO2009017467A1 (en) 2007-07-27 2009-02-05 Elan Pharma International Limited Treatment of amyloidogenic diseases
US8784810B2 (en) 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
US8003097B2 (en) 2007-04-18 2011-08-23 Janssen Alzheimer Immunotherapy Treatment of cerebral amyloid angiopathy
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
CN104922199A (zh) * 2015-07-14 2015-09-23 无限极（中国）有限公司 一种保护骨关节组合物及其应用
CA3099905A1 (en) 2017-05-11 2018-11-15 Avicenna Nutracetical, Llc Methods for producing collagen
EP4031167A4 (en) * 2019-09-16 2023-07-19 Figene, LLC TREATMENT OF DEGENERATIVE DISC DISEASE AND STIMULATION OF PROTEOGLYCAN SYNTHESIS BY CONDITIONED MEDIUM OF FIBROBLASTS AND THEIR FORMULATIONS

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4350682A (en) * 1979-05-11 1982-09-21 Lescarden Ltd. Cartilage extraction processes and products
JP2633881B2 (ja) * 1986-06-30 1997-07-23 マサチューセッツ インスティテュート オブ テクノロジー 免疫調節組成物及びそれらの使用
CA1302880C (en) * 1986-07-25 1992-06-09 Peter Koepff Agents for the treatment of arthroses
US5849298A (en) * 1987-06-24 1998-12-15 Autoimmune Inc. Treatment of multiple sclerosis by oral administration of bovine myelin
US5399347A (en) * 1987-06-24 1995-03-21 Autoimmune, Inc. Method of treating rheumatoid arthritis with type II collagen
JP2512796B2 (ja) * 1987-06-24 1996-07-03 オートイミュン・インコーポレイテッド 自己抗原の経口投与による自己免疫疾患の治療法
US5843445A (en) * 1987-06-24 1998-12-01 Autoimmune, Inc. Method of treating rheumatoid arthritis with type II collagen
CA1340012C (en) * 1987-08-17 1998-08-25 Trustees Of Leland Stanford Jr. University Peptide determinant associated with immunity
BR9007950A (pt) * 1989-12-20 1992-10-27 Brigham & Womens Hospital Metodo para tratamento ou prevencao da manifestacao de uma doenca auto-imune em um mamifero,formulacao farmaceutica,metodo para tratamento de uma doenca auto-imune,e metodo para tratamento de um mamifero acometido de doenca auto-imune
US5075112A (en) * 1990-02-12 1991-12-24 Cartilage Technologies Inc. Method of and dosage unit for inhibiting angiogenesis or vascularization in an animal using shark cartilage
ATE157257T1 (de) * 1990-03-02 1997-09-15 Autoimmune Inc Verstärkung der unterdrückungsregulation von autoimmunkrankheiten durch orale oder enterale verabreichung von autoantigenen
JP2635444B2 (ja) * 1990-10-15 1997-07-30 オートイミューン インク 自己抗体の経口投与による自己免疫性疾患の治療
DE4125400C2 (de) * 1991-07-31 2000-08-17 Edwin Klaus Verwendung von unlöslichem Kollagen zur Behandlung von degenerativen, nicht entzündlichen Gelenkprozessen

Also Published As

Publication number Publication date
JP2635444B2 (ja) 1997-07-30
KR0140841B1 (ko) 1998-06-01
EP0553291A1 (en) 1993-08-04
NO314878B1 (no) 2003-06-10
WO1992006708A1 (en) 1992-04-30
ATE319474T1 (de) 2006-03-15
HUT69942A (en) 1995-09-28
NO931372L (no) 1993-05-18
IL99754A (en) 1996-08-04
US6019971A (en) 2000-02-01
ES2258261T3 (es) 2006-08-16
JPH05508662A (ja) 1993-12-02
DE69133516D1 (de) 2006-05-04
AU3040995A (en) 1995-11-30
CA2092905A1 (en) 1992-04-16
AU9023791A (en) 1992-05-20
EP0553291A4 (en) 1994-11-30
KR930702026A (ko) 1993-09-08
EP0553291B1 (en) 2006-03-08
AU693232B2 (en) 1998-06-25
DE69133516T2 (de) 2006-08-10
CA2092905C (en) 2002-01-08
HU9301089D0 (en) 1993-07-28
IL99754A0 (en) 1992-08-18

Similar Documents

Publication Publication Date Title
NO931372L (no) Behandling av autoimmunsykdommer ved oral administrering av autoantigener
ES2190784T3 (es) Supresion de enfermedades autoinmunes por antigenos espectadores.
DK651689A (da) Oralt autoantigenholdigt praeparat
GR3033634T3 (en) Improved treatment of autoimmune diseases by aerosol administration of auto antigens.
EA200401473A1 (ru) Предотвращение и лечение амилоидогенного заболевания
NO923395D0 (no) Forsterkning av ned-reguleringen av autoimmune sykdommer ved oral administrasjon av autoantigener
DK0681479T3 (da) Immunterapeutisk præparat
SU1739559A1 (ru) Штамм вируса aphtae epizooticae типа o, используемый для изготовления диагностических сывороток и антигенных препаратов

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees